Research presented today by University of Michigan Medical School highlights FT011's ground-breaking treatment potential from human expression profiles in chronic kidney disease study supported by animal model data The research demonstrated that treatment with FT011 results in a remarkable reversal in the activation of genetic markers associated with fibrosis Fibrosis is responsible for 45 percent of all deaths globally - FT011 is a novel drug with potential to treat chronic fibrosis in multiple organs such as the kidneys, skin, lungs, heart, and eyes Certa Therapeutics is a clinical stage biotechnology company based in Melbourne, Australia, developing innovative therapies for the treatment of fibrotic diseases ANN ARBOR, Mich., Nov. 4, 2022 /PRNewswire/ New research presented today by the University of Michigan reveals ground-breaking results for Certa Therapeutics' FT011, a novel potential treatment of serious inflammatory and fibrotic diseases. The results in a chronic kid
SINGAPORE, Nov. 4, 2022 /PRNewswire/ HashKey Capital Singapore Pte. Ltd. ("HashKey Capital Singapore", and together with its affiliates, the "HashKey Group") announced at Singapore Fintech Festival 2022 that it has received its in-principle approval for the Capital Markets Services ("CMS") license from the Monetary Authority of Singapore ("MAS") as a licensed fund management company (LFMC). When granted, the CMS license will allow HashKey Capital Singapore to conduct fund management services from Singapore. HashKey Capital Singapore, part of HashKey Capital, prides itself as a company which takes the next step in bringing digital assets closer to mainstream institutional adoption. "Singapore is quickly becoming the region's epicentre of Web3 innovation. Being recognised by the MAS as a licensed fund management company will allow HashKey Capital Singapore to contribute to and support the local Web3 community, which is considered a signif